|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, hepatitis B surface antigen fabricated chitosan-polyethylene glycol nanocomposite (HBsAg-CS-PEG NC) was prepared by in situ ionic gelation method which brought about highly stable nanoformulation that was characterised by electron microscopy, atomic force microscopy (AFM) Fourier transform infrared spectroscopy (FTIR).
|
31669465 |
2020 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Current HBV treatments using nucleos(t)ide analogs (NAs) and PEG interferons cannot fully alleviate this burden as they do not affect the transcriptional activity of the tenacious covalently closed circular DNA (cccDNA) responsible for viral persistence.
|
30952041 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the measurement of HBV RNA prior to PEG-IFN-based therapy could identify patients with high probability of MVR.
|
31446638 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis B surface antigen (HBsAg) decline was significantly associated with elevated CD86<sup>+</sup> pDC% (r = 0.348, P = 0.015) during PEG-IFN-α-2a treatment.
|
29791282 |
2018 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).
|
29456079 |
2018 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with S267F variant tended to have more virological response, sustained response with hepatitis B surface antigen (HBsAg) loss at 24 weeks following PEG-IFN treatment.
|
28635613 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the role of adding PEGylated interferon (PEG IFN) to ongoing tenofovir treatment in chronic HBV patients for achieving HBsAg clearance.
|
28611343 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inclusion criteria for patients were as follows: (1) treatment-naive and treated with PEG IFN-α/RBV, (2) HCV RNA was present in serum for over 6 months before treatment, (3) negative for hepatitis B (HBV) or HIV infection and (4) lacked any other hepatic diseases.All participants in this study were Chinese Han population and infected with HCV genotype 1b and treated with subcutaneous PEG IFN-α at a dose of 180 µg once a week with the addition of 800-1000 mg/d RBV according to weight orally for 48 weeks.
|
29654010 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus.
|
29089529 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nucleot(s)ide analogues and peginterferon (PEG-IFN) treatment are the only approved therapies for chronic hepatitis B virus (HBV) infection.
|
28696237 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of quantitative serum hepatitis B core-related antigen (HBcrAg) in patients with chronic hepatitis B (CHB) receiving pegylated interferon (PEG-IFN) is unclear.
|
26678018 |
2016 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to investigate the association between single nucleotide polymorphisms (SNPs) G-201A of the IP-10 gene and treatment response to pegylated interferon (PEG-IFN) in patients with hepatitis B e antigen (HBeAg)-positive CHB.
|
26376789 |
2016 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The choice of patients with higher chance of sustained response (SR) to PEG-IFN can be made with pre-treatment and on-treatment factors; recent studies evidenced the role of early drop of serum hepatitis B surface antigen (HBsAg) as predictor of SR.
|
27793564 |
2016 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Viral genotype and hepatitis B surface antigen (HBsAg) decline were the most important predictive factor for PEG-IFN response.
|
27017932 |
2016 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.
|
27629859 |
2016 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, in HBV several retrospective studies yielded conflicting results of the association of IL28B with PEG-IFN-induced treatment response.
|
26284971 |
2015 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 212 hepatitis B e antigen (HBeAg)-positive patients treated with PEG-IFN monotherapy were enrolled in this study.
|
24517415 |
2015 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 212 hepatitis B e antigen (HBeAg)-positive patients treated with a 48weeks of PEG-IFN monotherapy were enrolled initially and 127 patients were followed for 48weeks posttreatment.
|
25640825 |
2015 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 210 patients with chronic hepatitis C genotype 1 of high viral load (baseline serum hepatitis C virus RNA > 5.0 log10 IU/mL) were divided into two groups by type of treatment: triple therapy with telaprevir, pegylated-interferon-α (PEG-IFNα), and ribavirin (RBV) for 24 wk (n = 88), or dual therapy with PEG-IFNα and RBV for 48 wk (n = 122).
|
25914481 |
2015 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hepatitis B surface antigen (HBsAg) loss was observed in 1 patient (2.5%); 56 patients (88%) showed at the time of diagnosis of CHB another infectious diseases that required specific treatment before PEG-IFN; this treatment was also affected by an higher incidence of side-effects (>50%).
|
24631900 |
2014 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the predictive factors associated with response to pegylated interferon (PEG-IFN) therapy, hepatitis B surface antigen quantification is considered to be a surrogate marker for monitoring response to PEG-IFN.
|
25309066 |
2014 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For HBeAg-positive patients and HBeAg-negative patients with genotype D infection, PEG-IFN therapy could be terminated early at week 12 or 24 in primary non-responders defined by the Hepatitis B surface antigen stopping rules.
|
24738850 |
2014 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis B virus surface antigen (HBsAg) became negative in six PEG-IFNa-treated patients until the end of long-term follow-up (10%).
|
24585488 |
2014 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although many patients prefer potent long-term nucleos(t)ide analogues (NAs) as the first-line therapy because they are convenient to use and well-tolerated, a finite duration of pegylated interferon (PEG-IFN) is still an attractive strategy because it provides higher rates of off-therapy host immune control over hepatitis B virus (HBV) compared with NAs.
|
24373087 |
2014 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the predictive effect of baseline hepatitis B surface antigen (HBsAg) on response to pegylated interferon (PEG-IFN)-α2b in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients.
|
25009392 |
2014 |